Taho Pharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 29

Employees

  • Stock Symbol
  • 6467

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $7.96
  • (As of Friday Closing)

Taho Pharmaceuticals General Information

Description

Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.

Contact Information

Website
www.tahopharma.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 3F, No.550, Ruiguang Road
  • Taipei
  • Taiwan
+886 02
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
TAI
Vertical(s)
Manufacturing, HealthTech
Corporate Office
  • 3F, No.550, Ruiguang Road
  • Taipei
  • Taiwan
+886 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Taho Pharmaceuticals Stock Performance

As of 13-Nov-2026, Taho Pharmaceuticals’s stock price is $7.96. Its current market cap is $477M with 59.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.96 $7.27 $3.10 - $9.52 $477M 59.9M 1.15M -$0.15

Taho Pharmaceuticals Financials Summary

As of 30-Jun-2026, Taho Pharmaceuticals has a trailing 12-month revenue of $63.8K.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 170,861 173,436 53,904
Revenue 64 270 0 34
EBITDA (7,528) (6,765) (5,066) (3,623)
Net Income (7,672) (6,873) (5,218) (3,874)
Total Assets 11,426 14,568 17,051 9,216
Total Debt 269 362 506 704
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Taho Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Taho Pharmaceuticals‘s full profile, request access.

Request a free trial

Taho Pharmaceuticals Patents

  • 68

    Total Documents Applications and Grants

  • Total Patents Families

  • 34

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Taho Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4836773-A1 Naloxone buccal film product and uses thereof Pending 02-Jan-2025
AU-2025205781-A1 Naloxone buccal film product and uses thereof Pending 05-Jan-2024
WO-2025147530-A1 Naloxone buccal film product and uses thereof Inactive 05-Jan-2024
AU-2022288053-A1 Apixaban film product and uses thereof Active 08-Jun-2021
AU-2022288053-B2 Apixaban film product and uses thereof Active 08-Jun-2021 A61K31/4545
To view Taho Pharmaceuticals’s complete patent history, request access »

Taho Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Taho Pharmaceuticals Investments (1)

Taho Pharmaceuticals’s most recent deal was a Seed Round with Mithradote Bio for . The deal was made on 02-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Mithradote Bio 02-Oct-2024 Seed Round Drug Discovery
To view Taho Pharmaceuticals’s complete investments history, request access »

Taho Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Taho Pharmaceuticals’s complete esg history, request access »

Taho Pharmaceuticals FAQs

  • When was Taho Pharmaceuticals founded?

    Taho Pharmaceuticals was founded in 2010.

  • Where is Taho Pharmaceuticals headquartered?

    Taho Pharmaceuticals is headquartered in Taipei, Taiwan.

  • What is the size of Taho Pharmaceuticals?

    Taho Pharmaceuticals has 29 total employees.

  • What industry is Taho Pharmaceuticals in?

    Taho Pharmaceuticals’s primary industry is Drug Delivery.

  • Is Taho Pharmaceuticals a private or public company?

    Taho Pharmaceuticals is a Public company.

  • What is Taho Pharmaceuticals’s stock symbol?

    The ticker symbol for Taho Pharmaceuticals is 6467.

  • What is the current stock price of Taho Pharmaceuticals?

    As of 13-Nov-2026 the stock price of Taho Pharmaceuticals is $7.96.

  • What is the current market cap of Taho Pharmaceuticals?

    The current market capitalization of Taho Pharmaceuticals is $477M.

  • What is Taho Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Taho Pharmaceuticals is $63.8K.

  • What is Taho Pharmaceuticals’s annual earnings per share (EPS)?

    Taho Pharmaceuticals’s EPS for 12 months was -$0.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process